These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

908 related items for PubMed ID: 16865225

  • 1. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients.
    Bevelacqua V, Libra M, Mazzarino MC, Gangemi P, Nicotra G, Curatolo S, Massimino D, Plumari A, Merito P, Valente G, Stivala F, La Greca S, Malaponte G.
    Int J Mol Med; 2006 Sep; 18(3):415-23. PubMed ID: 16865225
    [Abstract] [Full Text] [Related]

  • 2. Inflammatory status in patients with chronic renal failure: the role of PTX3 and pro-inflammatory cytokines.
    Malaponte G, Libra M, Bevelacqua Y, Merito P, Fatuzzo P, Rapisarda F, Cristina M, Naselli G, Stivala F, Mazzarino MC, Castellino P.
    Int J Mol Med; 2007 Oct; 20(4):471-81. PubMed ID: 17786277
    [Abstract] [Full Text] [Related]

  • 3. Goeckerman's therapy for psoriasis with special reference to serum pentraxin 3 level.
    Ctirad A, Lenka B, David P, Zdenek F, Kveta H, Karel E, Jan K.
    Int J Dermatol; 2008 Oct; 47(10):1011-4. PubMed ID: 18986345
    [Abstract] [Full Text] [Related]

  • 4. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y, Yoshizaki A, Ogawa F, Komura K, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Takehara K, Sato S.
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure.
    Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, Sagara M, Kubota I.
    Am Heart J; 2008 Jan; 155(1):75-81. PubMed ID: 18082493
    [Abstract] [Full Text] [Related]

  • 7. The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation.
    Napoleone E, di Santo A, Peri G, Mantovani A, de Gaetano G, Donati MB, Lorenzet R.
    J Leukoc Biol; 2004 Jul; 76(1):203-9. PubMed ID: 15226367
    [Abstract] [Full Text] [Related]

  • 8. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease.
    Karadag F, Kirdar S, Karul AB, Ceylan E.
    Eur J Intern Med; 2008 Mar; 19(2):104-8. PubMed ID: 18249305
    [Abstract] [Full Text] [Related]

  • 9. Pentraxin 3 and C-reactive protein in severe meningococcal disease.
    Sprong T, Peri G, Neeleman C, Mantovani A, Signorini S, van der Meer JW, van Deuren M.
    Shock; 2009 Jan; 31(1):28-32. PubMed ID: 18650775
    [Abstract] [Full Text] [Related]

  • 10. Serum levels of interleukin-8, tumor necrosis factor-α and γ-interferon in Egyptian psoriatic patients and correlation with disease severity.
    Abdel-Hamid MF, Aly DG, Saad NE, Emam HM, Ayoub DF.
    J Dermatol; 2011 May; 38(5):442-6. PubMed ID: 21352285
    [Abstract] [Full Text] [Related]

  • 11. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions.
    Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, Emura I, Iwanari H, Sagara M, Tanaka T, Hamakubo T, Kodama T, Naito M.
    J Pathol; 2008 May; 215(1):48-55. PubMed ID: 18220316
    [Abstract] [Full Text] [Related]

  • 12. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity.
    Arican O, Aral M, Sasmaz S, Ciragil P.
    Mediators Inflamm; 2005 Oct 24; 2005(5):273-9. PubMed ID: 16258194
    [Abstract] [Full Text] [Related]

  • 13. [Inflammatory status in patients with end-stage renal disease: role of monocyte activation].
    Liang M, Wang L, Hou FF, Liu J, Liu ZQ, Tian JW.
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug 24; 23(8):781-4. PubMed ID: 12919896
    [Abstract] [Full Text] [Related]

  • 14. [Pentraxin 3].
    Inoue K.
    Rinsho Byori; 2011 Jul 24; 59(7):694-701. PubMed ID: 21874796
    [Abstract] [Full Text] [Related]

  • 15. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity.
    Jacob SE, Nassiri M, Kerdel FA, Vincek V.
    Mediators Inflamm; 2003 Oct 24; 12(5):309-13. PubMed ID: 14760939
    [Abstract] [Full Text] [Related]

  • 16. Increased peripheral circulating inflammatory cells and plasma inflammatory markers in patients with variant angina.
    Li JJ, Zhang YP, Yang P, Zeng HS, Qian XW, Zhang CY, Zhu CG, Li J, Nan JL.
    Coron Artery Dis; 2008 Aug 24; 19(5):293-7. PubMed ID: 18607165
    [Abstract] [Full Text] [Related]

  • 17. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.
    Markham T, Mullan R, Golden-Mason L, Rogers S, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ.
    J Am Acad Dermatol; 2006 Jun 24; 54(6):1003-12. PubMed ID: 16713454
    [Abstract] [Full Text] [Related]

  • 18. Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease.
    Deeva I, Mariani S, De Luca C, Pacifico V, Leoni L, Raskovic D, Kharaeva Z, Korkina L, Pastore S.
    Cytokine; 2010 Feb 24; 49(2):163-70. PubMed ID: 19879157
    [Abstract] [Full Text] [Related]

  • 19. Relationship between triiodothyronine and proinflammatory cytokines in chronic heart failure.
    Lubrano V, Pingitore A, Carpi A, Iervasi G.
    Biomed Pharmacother; 2010 Mar 24; 64(3):165-9. PubMed ID: 19926244
    [Abstract] [Full Text] [Related]

  • 20. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.
    Kanelleas A, Liapi C, Katoulis A, Stavropoulos P, Avgerinou G, Georgala S, Economopoulos T, Stavrianeas NG, Katsambas A.
    Clin Exp Dermatol; 2011 Dec 24; 36(8):845-50. PubMed ID: 21790728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.